POC testing is described as medical diagnostic testing at or near the point of care that is, at time and place of patient care. The purpose of POCT is to pro- vide immediate information to physicians about the patient’s condition. Point of care testing (POCT) is an important diagnostic tool used in various locations in the hospital, in critical care settings such as the intensive care unit (ICU), the operating room (OR), and the emergency department (ED).
Market leaders operating in the market have undertaken various organic growth strategies in the point of care diagnostics market. The point of care diagnostics market majorly consists of the players such F. Hoffmann-La Roche Ltd., Abbott, bioMérieux SA, Johnson & Johnson Services, Inc., Nova Biomedical, Siemens AG, Bio Rad Laboratories Inc., BD, Danaher Corporation, and PTS Diagnostics amongst others. Several organic approaches, such as product launches, and expansion in the point of care diagnostics market, have resulted in the positive growth of the market. Product launches help the company to strengthen its product offering and the customer base, which allows the company to hold a strong position in the market. Similarly, utilizing expansion activities, it is easy to venture into untapped economies and use the opportunities being offered
Hoffmann-La Roche Ltd and Abbott Laboratories -Notable Market Players in Point of Care Diagnostics Market
The point of care diagnostics market is witnessing substantial growth amid the COVID-19 pandemic. Certain factors such as sudden rise in coronavirus infections and exponential growth in COVID-19 diagnostic kits played a prominent role in the growth of the point of care diagnostics market during the pandemic. In addition, the growing demand for rapid test kits for faster diagnosis at public places is also estimated to have a positive impact on the market growth.
Below is the list of the growth strategies done by the players operating in the point of care diagnostics market:
| Year | News |
| Feb-2021 | Roche announces the filing for FDA Emergency Use Authorization for SARS-CoV-2 Rapid Antigen Test, allowing healthcare professionals to make fast decisions at the point of care. |
| Mar-2021 | bioMérieux, announced BioFire Diagnostics, its subsidiary specialized in molecular syndromic infectious disease testing, has received U.S. Food and Drug Administration (FDA) De Novo authorization for the BIOFIRE RP2.1 Panel. |
| Apr-2020 | Nova Biomedical announced the FDA has cleared its Stat Profile Prime Plus critical care blood gas analyzer for point-of-care use. This clearance allows POC personnel to perform bedside critical care testing with results in one minute. |
